BCTX - BriaCell to get US Australian patent linked to personalized cancer immunotherapy

BriaCell Therapeutics ( NASDAQ: BCTX ) stock rose ~6% on Tuesday after the company said it will get a patent from the U.S. Patent and Trademark Office (USPTO) for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer.

The patent will be issued on Jan. 24 as U.S. Patent No. 11,559,574 with the term extending to May 25, 2040. The patent is titled 'Whole-cell cancer vaccines and methods for selection thereof.'

The company said its novel technology involves the development of several HLA specific whole-cell immunotherapies in advance, and selection of the appropriate off-the-shelf (pre-made) immunotherapies for each patient based on the patient's HLA type using a saliva test.

In addition, BriaCell said it was awarded an Australian patent, No. 2017224232 extending till Feb. 27, 2037, covering composition of matter and method of use for its whole-cell cancer immunotherapy technology in Australia.

"We are extremely excited with the new patent for our novel personalized off-the-shelf cancer immunotherapy technology, which provides patent protection for the Bria-OTS immunotherapy cell lines under development and further validates and extends our whole-cell cancer immunotherapy technology," said BriaCell's President and CEO William Williams.

BriaCell noted that it expects to start its Bria-OTS clinical study in H1 2023.

For further details see: